id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-N-1262-0025,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; KISQALI (ribociclib),Notice,Notice of Approval,2024-10-15T04:00:00Z,2024,10,,,2024-10-15T14:35:39Z,2024-23651,0,0,09000064867ce6bb
FDA-2018-N-1262-0024,FDA,FDA-2018-N-1262,"Notice of Approval of Product Under Voucher: Rare Pediatric Disease
Priority Review Voucher; TREMFYA (guselkumab)",Notice,Announcement,2024-10-11T04:00:00Z,2024,10,2024-10-11T04:00:00Z,,2024-10-11T14:35:40Z,2024-23629,0,0,09000064867c9627
FDA-2018-N-1262-0023,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; OPZELURA (ruxolitinib),Notice,General Notice,2024-09-11T04:00:00Z,2024,9,,,2024-09-11T13:16:31Z,2024-20556,0,0,09000064866ea193
FDA-2018-N-1262-0022,FDA,FDA-2018-N-1262,"Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; VYVGART
HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)",Notice,Announcement,2024-07-17T04:00:00Z,2024,7,2024-07-17T04:00:00Z,,2024-07-17T13:00:19Z,2024-15695,0,0,09000064865f4739
FDA-2018-N-1262-0018,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher,Notice,Notice of Approval,2024-01-23T05:00:00Z,2024,1,2024-01-23T05:00:00Z,,2024-01-23T15:06:50Z,2024-01156,0,0,09000064863b8649
FDA-2018-N-1262-0019,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher,Notice,Notice of Approval,2024-01-23T05:00:00Z,2024,1,2024-01-23T05:00:00Z,,2024-01-23T15:31:45Z,2024-01164,0,0,09000064863b88d4
FDA-2018-N-1262-0021,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher,Notice,Notice of Approval,2024-01-23T05:00:00Z,2024,1,2024-01-23T05:00:00Z,,2024-01-23T15:57:05Z,2024-01160,0,0,09000064863b9236
FDA-2018-N-1262-0020,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher,Notice,Notice of Approval,2024-01-23T05:00:00Z,2024,1,2024-01-23T05:00:00Z,,2024-01-23T15:55:32Z,2024-01163,0,0,09000064863b9166